Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. (Record no. 1205)

MARC details
000 -LEADER
fixed length control field 04806nam a22008177a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 130807s20132013 xxu||||| |||| 00| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 1079-5642
040 ## - CATALOGING SOURCE
Original cataloging agency Ovid MEDLINE(R)
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
PMID 23175674
245 ## - TITLE STATEMENT
Title Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors.
251 ## - Source
Source Arteriosclerosis, Thrombosis & Vascular Biology. 33(2):393-9, 2013 Feb.
252 ## - Abbreviated Source
Abbreviated source Arterioscler Thromb Vasc Biol. 33(2):393-9, 2013 Feb.
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Year 2013
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Manufacturer FY2013
266 ## - Date added to catalog
Date added to catalog 2013-09-17
501 ## - WITH NOTE
Local holdings Available online from MWHC library: 1995 - present
520 ## - SUMMARY, ETC.
Abstract CONCLUSIONS: Pioglitazone slowed progression of CIMT, independent of improvement in hyperglycemia, insulin resistance, dyslipidemia, and systemic inflammation in prediabetes. These results suggest a possible direct vascular benefit of pioglitazone.
520 ## - SUMMARY, ETC.
Abstract METHODS AND RESULTS: CIMT was measured in 382 participants at the beginning and up to 3 additional times during follow-up of the Actos Now for Prevention of Diabetes trial. During an average follow-up of 2.3 years, the mean unadjusted annual rate of CIMT progression was significantly (P=0.01) lower with pioglitazone treatment (4.76x10(-3) mm/year; 95% CI: 2.39x10(-3)-7.14x10(-3) mm/year) compared with placebo (9.69x10(-3) mm/year; 95% CI: 7.24x10(-3)-12.15x10(-3) mm/year). High-density lipoprotein cholesterol, fasting and 2-hour glucose, HbA(1c), fasting insulin, Matsuda insulin sensitivity index, adiponectin, and plasminogen activator inhibitor-1 levels improved significantly with pioglitazone treatment compared with placebo (P<0.001). However, the effect of pioglitazone on CIMT progression was not attenuated by multiple methods of adjustment for traditional, metabolic, and inflammatory risk factors and concomitant medications, and was independent of changes in risk factors during pioglitazone treatment.
520 ## - SUMMARY, ETC.
Abstract OBJECTIVE: To determine whether changes in standard and novel risk factors during the Actos Now for Prevention of Diabetes trial explained the slower rate of carotid intima media thickness (CIMT) progression with pioglitazone treatment in persons with prediabetes.
546 ## - LANGUAGE NOTE
Language note English
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Carotid Artery Diseases/pc [Prevention & Control]
9 (RLIN) 607
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Diabetes Mellitus, Type 2/pc [Prevention & Control]
9 (RLIN) 608
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Hypoglycemic Agents/tu [Therapeutic Use]
9 (RLIN) 261
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Prediabetic State/dt [Drug Therapy]
9 (RLIN) 609
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Thiazolidinediones/tu [Therapeutic Use]
9 (RLIN) 610
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Adiponectin/bl [Blood]
9 (RLIN) 611
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Adult
9 (RLIN) 13
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Aged
9 (RLIN) 2
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Biological Markers/bl [Blood]
9 (RLIN) 399
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Blood Glucose/de [Drug Effects]
9 (RLIN) 612
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Blood Glucose/me [Metabolism]
9 (RLIN) 613
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Carotid Artery Diseases/bl [Blood]
9 (RLIN) 614
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Carotid Artery Diseases/di [Diagnosis]
9 (RLIN) 615
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Carotid Artery Diseases/et [Etiology]
9 (RLIN) 616
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Carotid Intima-Media Thickness
9 (RLIN) 617
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Chi-Square Distribution
9 (RLIN) 39
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Cholesterol, HDL/bl [Blood]
9 (RLIN) 618
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Diabetes Mellitus, Type 2/bl [Blood]
9 (RLIN) 619
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Diabetes Mellitus, Type 2/di [Diagnosis]
9 (RLIN) 620
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Diabetes Mellitus, Type 2/et [Etiology]
9 (RLIN) 621
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Disease Progression
9 (RLIN) 468
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Double-Blind Method
9 (RLIN) 622
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Female
9 (RLIN) 7
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Hemoglobin A, Glycosylated/me [Metabolism]
9 (RLIN) 623
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Humans
9 (RLIN) 11
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Insulin/bl [Blood]
9 (RLIN) 624
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Linear Models
9 (RLIN) 487
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Male
9 (RLIN) 14
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Middle Aged
9 (RLIN) 15
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Multivariate Analysis
9 (RLIN) 302
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Plasminogen Activator Inhibitor 1/bl [Blood]
9 (RLIN) 625
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Prediabetic State/bl [Blood]
9 (RLIN) 626
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Prediabetic State/co [Complications]
9 (RLIN) 627
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Prediabetic State/di [Diagnosis]
9 (RLIN) 628
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Prospective Studies
9 (RLIN) 177
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Risk Assessment
9 (RLIN) 514
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Risk Factors
9 (RLIN) 311
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Time Factors
9 (RLIN) 48
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Treatment Outcome
9 (RLIN) 18
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element United States
9 (RLIN) 82
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Institution MedStar Health Research Institute
657 ## - INDEX TERM--FUNCTION
Medline publication type Journal Article
657 ## - INDEX TERM--FUNCTION
Medline publication type Multicenter Study
657 ## - INDEX TERM--FUNCTION
Medline publication type Randomized Controlled Trial
657 ## - INDEX TERM--FUNCTION
Medline publication type Research Support, Non-U.S. Gov't
657 ## - INDEX TERM--FUNCTION
Medline publication type Research Support, U.S. Gov't, Non-P.H.S.
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Ratner, Robert E
9 (RLIN) 606
790 ## - Authors
All authors Banerji M, Bray GA, Buchanan TA, Clement SC, DeFronzo RA, Henry RR, Hodis HN, Kitabchi AE, Mack WJ, Mudaliar S, Musi N, Ratner RE, Reaven PD, Saremi A, Schwenke DC, Stentz FB, Tripathy D
856 ## - ELECTRONIC LOCATION AND ACCESS
DOI <a href="http://dx.doi.org/10.1161/ATVBAHA.112.300346">http://dx.doi.org/10.1161/ATVBAHA.112.300346</a>
Public note http://dx.doi.org/10.1161/ATVBAHA.112.300346
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Source of classification or shelving scheme Other/Generic Classification Scheme
Item type description Article
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection Home library Current library Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
          MedStar Authors Catalog MedStar Authors Catalog 09/17/2013   23175674 23175674 09/17/2013 09/17/2013 Journal Article

Powered by Koha